\-\ Texto\\:\\ \ \(0\)\
\-\ right\\ nasal\\ mass\\,\\ diplopia\\ on\\ confrontational\\ testing\ \(1\)\
\-\ chemotherapy\ \(327\)\
\-\ mass\\ in\\ right\\ maxillary\\ sinus\\ with\\ erosion\\ through\\ inferior\\ orbital\\ floor\\/maxillary\\ roof\\,\\ with\\ extension\\ into\\ infero\\-medial\\ orbital\\ fat\\ of\\ right\\ orbit\\.\ \(0\)\
\-\ secondary\\ orbital\\ large\\ cell\\ lymphoma\\,\\ extraconal\\ masses\ \(0\)\
\-\ aggressive\\ lymphoma\ \(1\)\
\-\ squamous\\ cell\\ carcinoma\ \(52\)\
\-\ adenocarcinoma\ \(192\)\
\-\ primary\\ melanoma\ \(3\)\
\-\ inverting\\ papilloma\ \(2\)\
\-\ several\\ months\\ history\\ of\\ right\\ nasal\\ congestion\\ and\\ increasing\\ diplopia\\,\\ od\\.\ \(0\)\
\-\ this\\ was\\ an\\ aggressive\\ nhl\\ which\\ originated\\ in\\ the\\ right\\ maxillary\\ sinus\\ and\\ \\(uncharacteristically\\)\\ eroded\\ through\\ the\\ sinus\\ wall\\.\\ invading\\ the\\ right\\ extra\\-conal\\ orbit\\,\\ with\\ evident\\ mass\\ effect\\ on\\ the\\ right\\ globe\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ orbital\\:\\ 0\\.12160033467506226\ \(0\)\
\-\ diplopia\\:\\ 0\\.09973754054954807\ \(0\)\
\-\ sinus\\:\\ 0\\.09375476908927313\ \(0\)\
\-\ maxillary\\:\\ 0\\.09344767395149932\ \(0\)\
\-\ floor\\/maxillary\\:\\ 0\\.08815518423966498\ \(0\)\
\-\ uncharacteristically\\:\\ 0\\.08815518423966498\ \(0\)\
\-\ orbit\\:\\ 0\\.08609317834899298\ \(0\)\
\-\ nasal\\:\\ 0\\.08461101890591852\ \(0\)\
\-\ aggressive\\:\\ 0\\.08361578871473725\ \(0\)\
\-\ confrontational\\:\\ 0\\.08122371243406554\ \(0\)\
\-\ extra\\-conal\\:\\ 0\\.08122371243406554\ \(0\)\
\-\ infero\\-medial\\:\\ 0\\.07716906135298389\ \(0\)\
\-\ nhl\\:\\ 0\\.07023758954738443\ \(0\)\
\-\ originated\\:\\ 0\\.06736076882286662\ \(0\)\
\-\ extraconal\\:\\ 0\\.06618293846630278\ \(0\)\
\-\ inverting\\:\\ 0\\.06618293846630278\ \(0\)\
\-\ eroded\\:\\ 0\\.06330611774178498\ \(0\)\
\-\ right\\:\\ 0\\.06311421963772917\ \(0\)\
\-\ od\\:\\ 0\\.05925146666070334\ \(0\)\
\-\ invading\\:\\ 0\\.056800242080373486\ \(0\)\
\-\ roof\\:\\ 0\\.05177932264240113\ \(0\)\
\-\ globe\\:\\ 0\\.0496537082225644\ \(0\)\
\-\ lymphoma\\:\\ 0\\.04884397268778971\ \(0\)\
\-\ through\\:\\ 0\\.048539140368417374\ \(0\)\
\-\ congestion\\:\\ 0\\.04656635340606826\ \(0\)\
\-\ cell\\:\\ 0\\.04616481423162973\ \(0\)\
\-\ melanoma\\:\\ 0\\.0436117112771299\ \(0\)\
\-\ erosion\\:\\ 0\\.04315708753636233\ \(0\)\
\-\ papilloma\\:\\ 0\\.04293729846917458\ \(0\)\
\-\ squamous\\:\\ 0\\.041807894357368626\ \(0\)\
\-\ testing\\:\\ 0\\.04133387196842279\ \(0\)\
\-\ evident\\:\\ 0\\.039102436455280686\ \(0\)\
\-\ adenocarcinoma\\:\\ 0\\.036915544445632394\ \(0\)\
\-\ mass\\:\\ 0\\.03565383020842693\ \(0\)\
\-\ increasing\\:\\ 0\\.03502312444924711\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.030629457851408654\ \(0\)\
\-\ extension\\:\\ 0\\.030503273211816537\ \(0\)\
\-\ effect\\:\\ 0\\.030255582530692448\ \(0\)\
\-\ inferior\\:\\ 0\\.02899316361359063\ \(0\)\
\-\ masses\\:\\ 0\\.028885923979960874\ \(0\)\
\-\ several\\:\\ 0\\.027470928357223878\ \(0\)\
\-\ fat\\:\\ 0\\.025989123228816333\ \(0\)\
\-\ primary\\:\\ 0\\.025313842628956966\ \(0\)\
\-\ wall\\:\\ 0\\.02475159120238746\ \(0\)\
\-\ carcinoma\\:\\ 0\\.024219276700158665\ \(0\)\
\-\ secondary\\:\\ 0\\.023890299665088075\ \(0\)\
\-\ months\\:\\ 0\\.023339412946900673\ \(0\)\
\-\ into\\:\\ 0\\.02033326367959707\ \(0\)\
\-\ large\\:\\ 0\\.018685424318310797\ \(0\)\
\-\ which\\:\\ 0\\.015951445872425488\ \(0\)\
\-\ on\\:\\ 0\\.014477820247308561\ \(0\)\
\-\ \\,\\:\\ 0\\.01353550327586437\ \(0\)\
\-\ an\\:\\ 0\\.011816648642847299\ \(0\)\
\-\ history\\:\\ 0\\.011802145377070835\ \(0\)\
\-\ was\\:\\ 0\\.009882775222136868\ \(0\)\
\-\ this\\:\\ 0\\.009611372133141331\ \(0\)\
\-\ in\\:\\ 0\\.008427944602805099\ \(0\)\
\-\ \\(\\:\\ 0\\.0072236172624386055\ \(0\)\
\-\ \\)\\:\\ 0\\.007135376921133051\ \(0\)\
\-\ the\\:\\ 0\\.005529971388145032\ \(0\)\
\-\ and\\:\\ 0\\.0036001801146443692\ \(0\)\
\-\ with\\:\\ 0\\.003510125282696692\ \(0\)\
\-\ of\\:\\ 0\\.0023300760159597686\ \(0\)\
\-\ \\.\\:\\ 0\\.001419981443893851\ \(0\)\
